7 Current news of MorphoSys
rssAnalysis of Antibody-Antigen-Complex Structures to Allow More Efficient Engineering of Therapeutic Antibodies
10-13-2010
MorphoSys AG and Proteros Biostructures announced that they have been awarded a grant by the German Federal Ministry of Education and Research, BMBF. The funding of approximately EUR 850,000 supports both companies in establishing a new technology platform for efficient structural ...
Combination of Technologies Set to Increase Success Rates in Drug Development
10-11-2010
MorphoSys AG announced the acquisition of Sloning BioTechnology GmbH. The transaction will make MorphoSys the sole source of Sloning's state-of-the-art Slonomics technology, which improves the assembly and quality of protein libraries. By integrating Slonomics into its existing antibody ...
03-17-2009
MorphoSys AG announced that the European Patent Office has granted a European divisional patent stemming from MorphoSys's base HuCAL (Human Combinatorial Antibody Library) patent family, providing extended protection for the Company's core technology. The new patent (EP1143006) captures ...
AbD Serotec will use proprietary technology to generate antibodies against novel research targets provided by Sigma-Aldrich
02-28-2008
Sigma-Aldrich and MorphoSys AG announced a collaboration agreement to design, produce and distribute unique recombinant research antibodies using MorphoSys's proprietary HuCAL GOLD(R) technology. MorphoSys's AbD Serotec unit will develop and qualify unique antibodies from MorphoSys's ...
Dritte therapeutische Allianz für MorphoSys in Japan
03-29-2007
Die MorphoSys AG gab die Unterzeichnung eines Lizenzvertrags zur Nutzung der firmeneigenen HuCAL-Technologie mit Astellas Pharma Inc. bekannt. Im Rahmen der Vereinbarung gewährt MorphoSys Astellas Zugang zur seiner HuCAL GOLD-Antikörperbibliothek für den Einsatz in Astellas' pharmazeutischer ...
12-11-2006
AbD Serotec, eine Geschäftseinheit der MorphoSys AG, gab die Ergebnisse einer Untersuchung der Hokkaido Universität mit Forschungsantikörper aus der HuCAL GOLD-Antikörperbibliothek von MorphoSys bekannt. Die vollständig menschlichen, monoklonalen Mini-Antikörper aus der hochdurchsatzfähigen ...
01-06-2005
MorphoSys AG announced the extension of its agreement with Centocor Inc., a Johnson & Johnson company, until the end of 2007. The objective of the cooperation between MorphoSys and Centocor is the development of fully human therapeutic antibodies in a broad range of indications. ...
